Segment Information (Tables)

12 Months Ended

Dec. 31, 2015

Segment Information

Schedule of net revenues, cost of product sales and gross profit for each commercial product

        Net product sales, cost of product sales and gross profit for each of our commercial products were as follows (in thousands):

Year Ended December 31, 2015	Remodulin		Tyvaso		Adcirca		Orenitram		Unituxin		Total
Net product sales	$	572,795	$	470,069	$	278,829	$	118,434	$	20,443	$	1,460,570
Cost of product sales		12,373		23,925		16,504		12,569		3,665		69,036
Gross profit	$	560,422	$	446,144	$	262,325	$	105,865	$	16,778	$	1,391,534
Year Ended December 31, 2014
Net product sales	$	553,728	$	463,067	$	221,471	$	41,267	$	—	$	1,279,533
Cost of product sales		47,327		57,442		13,495		7,619		—		125,883
Gross profit	$	506,401	$	405,625	$	207,976	$	33,648	$	—	$	1,153,650
Year Ended December 31, 2013
Net product sales	$	491,179	$	438,793	$	176,972	$	—	$	—	$	1,106,944
Cost of product sales		59,314		60,831		10,982		—		—		131,127
Gross profit	$	431,865	$	377,962	$	165,990	$	—	$	—	$	975,817

Schedule of net revenues from external customers by geographic area

Total revenues from external customers by geographic area are as follows (in thousands):

Year Ended December 31,	2015		2014		2013
United States	$	1,353,002	$	1,180,759	$	1,032,435
Rest-of-World(1)		112,759		107,760		84,549
Total(2)	$	1,465,761	$	1,288,519	$	1,116,984

(1)	Primarily Europe.
(2)	Total includes other revenue of $5.2 million, $9.0 million and $10.0 million for the years ended December 31, 2015, 2014 and 2013, respectively.

Schedule of long-lived assets (property, plant and equipment) located by geographic area

        Long-lived assets (property, plant and equipment) located by geographic area are as follows (in thousands):

Year Ended December 31,	2015		2014
United States	$	481,219	$	462,377
Rest-of-World(1)		14,555		16,044
Total	$	495,774	$	478,421

(1)           Facilities principally located in the United Kingdom.